Addyi Side Effects: Incidence Rates Across Clinical Trials

What the Phase III Trials Actually Measured

The FDA's 2015 medical review of NDA 022526 pooled data from three key phase III randomized controlled trials: BEGONIA, VIOLET, and DAISY. Together these enrolled approximately 2,400 premenopausal women with hypoactive sexual desire disorder (HSDD). Each trial ran 24 weeks, with participants randomized to flibanserin 100 mg at bedtime or placebo. The full FDA medical review is publicly available.

Pooled Adverse Event Rates From BEGONIA, VIOLET, and DAISY

The table below reflects treatment-emergent adverse events (TEAEs) occurring in at least 2% of the flibanserin arm and at a higher rate than placebo, drawn directly from the FDA medical officer review.

| Adverse Event | Flibanserin 100 mg | Placebo | |---|---|---| | Dizziness | 11.4% | 2.2% | | Somnolence | 11.2% | 2.9% | | Nausea | 10.4% | 3.9% | | Fatigue | 9.2% | 5.5% | | Insomnia | 4.9% | 3.5% | | Dry mouth | 3.0% | 0.8% | | Anxiety | 3.5% | 2.7% | | Sedation | 2.5% | 0.4% |

These numbers come from the pooled safety population of 1,543 women on flibanserin and 1,905 on placebo across the three studies. The prescribing information confirms these figures.

Why CNS Effects Dominate the Adverse Event Profile

Flibanserin acts as a serotonin 5-HT1A agonist and 5-HT2A antagonist, with additional antagonism at dopamine D4 receptors. This mixed mechanism explains the CNS-heavy side effect burden. The FDA's clinical pharmacology review noted that peak plasma concentration occurs roughly 45 minutes after an evening dose, which is why bedtime administration partially offsets daytime sedation but does not eliminate morning-after effects in a meaningful subset of patients. See the clinical pharmacology review for full PK data.

Discontinuation Rates and Severity Classification

Roughly 13% of flibanserin-treated women discontinued due to adverse events across the pooled phase III population, compared with approximately 6% in the placebo arm. The FDA review classified discontinuations by primary reason: dizziness and somnolence together accounted for the largest share of drug-related dropouts. The statistical review documents these rates in detail.

Serious Adverse Events in the Trial Database

Serious adverse events (SAEs) were uncommon but not absent. The pooled dataset recorded SAEs in 1.5% of flibanserin recipients vs. 1.1% of placebo recipients. Syncope occurred in 0.4% of treated women vs. 0.2% placebo. Hypotension meeting protocol-defined criteria appeared in 0.2% of the flibanserin group. No trial deaths were attributed to the drug itself. A 2016 analysis in the Journal of Sexual Medicine summarized the integrated safety data from all three key studies.

The Alcohol Interaction Study: Where the Risk Becomes Acute

A dedicated drug-interaction study (Study A0081078, referenced in the FDA medical review) administered flibanserin with 0.4 g/kg or 0.8 g/kg of alcohol to 25 healthy volunteers. All six participants who received the higher alcohol dose plus flibanserin experienced at least one hypotensive episode; two required medical intervention for symptomatic hypotension. The mean systolic blood pressure nadir was 28 mmHg below baseline in the combination group. The FDA's drug interaction summary is embedded in the clinical pharmacology review.

This finding directly drove the REMS requirement. The FDA states in the approved labeling: "The risk of severe hypotension and syncope is increased when ADDYI is used with alcohol." Prescribers must counsel patients to avoid alcohol for at least two hours after taking a dose and not to take the drug until at least two hours after alcohol consumption has ended. Full REMS details are maintained on the FDA website.

CYP3A4 Inhibitor Interactions and Amplified Adverse Events

Flibanserin is metabolized primarily by CYP3A4, with minor contribution from CYP2C19. Co-administration with moderate or strong CYP3A4 inhibitors raises flibanserin plasma exposure substantially, which compounds adverse event risk. The FDA label lists contraindicated CYP3A4 inhibitors.

Fluconazole and Ketoconazole Interaction Data

A pharmacokinetic study showed that fluconazole 200 mg (a moderate-to-strong CYP3A4 inhibitor) increased flibanserin AUC by 7-fold and Cmax by approximately 2-fold. Ketoconazole 400 mg daily, a strong inhibitor, raised flibanserin AUC by approximately 4.5-fold in a separate PK sub-study. At these elevated exposures, CNS depression and hypotensive adverse events are expected to reach clinically dangerous levels. These interaction data appear in the clinical pharmacology review.

Commonly Prescribed Drugs That Require Caution

Several drugs frequently used by women of reproductive age are moderate CYP3A4 inhibitors: fluconazole (antifungal), ciprofloxacin (antibiotic), diltiazem (calcium channel blocker), and hormonal contraceptives at certain doses. The FDA label categorizes these as contraindicated or requiring close monitoring. A 2017 review in Pharmacotherapy examined CYP3A4 interaction risk across the flibanserin patient population.

Post-Market Safety: FAERS Reports and Real-World Data

The FDA Adverse Event Reporting System (FAERS) has accumulated post-market reports for flibanserin since its 2015 approval. Because FAERS is a passive surveillance database, absolute incidence calculations are not possible from it alone. However, the signal distribution confirms that dizziness, syncope, and somnolence remain the dominant reported adverse events outside controlled trial conditions. FAERS data can be queried via the FDA's public dashboard.

Syncope Reports in FAERS vs. Trial Rates

In the controlled trials, syncope occurred in 0.4% of treated women. Post-market FAERS reports suggest the real-world syncope rate may run higher, likely because alcohol co-use and CYP3A4 inhibitor co-prescribing are more common outside a trial setting than within one. A 2019 pharmacovigilance analysis published in Drug Safety examined FAERS reports through early 2019 and identified syncope and hypotension as disproportionately reported signals for flibanserin relative to other sexual dysfunction agents. Access the Drug Safety analysis here.

Falls and Driving Impairment: Under-Reported Signals

The FDA's 2015 advisory committee noted concern that next-morning sedation could impair driving performance. One small crossover study found that flibanserin produced driving simulation impairment comparable to a blood alcohol concentration of 0.05% when taken at bedtime and tested six hours later. Falls secondary to dizziness or orthostatic hypotension appear in FAERS but are not consistently coded under a single preferred term, which makes the true incidence difficult to quantify from real-world data alone. The original advisory committee briefing documents are available via the FDA.

Subgroup Differences in Adverse Event Rates

Menopausal Status

The three key trials enrolled only premenopausal women. Two additional open-label studies in postmenopausal women (Studies A0081064 and A0081065) found broadly similar adverse event profiles, though the FDA noted the postmenopausal dataset was smaller and powered for efficacy, not safety characterization. The approved indication remains premenopausal HSDD. The FDA label specifies the approved population.

Body Weight and CYP Polymorphisms

Women with lower body weight reached higher flibanserin peak plasma concentrations in PK modeling, which the FDA noted as a potential contributor to adverse event variability. Poor metabolizers at CYP2C19 show modestly elevated exposure compared to normal metabolizers. The clinical pharmacology review did not find these differences large enough to recommend dose adjustment, but they may explain some of the variability in somnolence severity between individual patients. The full PK sub-analysis is in the clinical pharmacology review.

Efficacy-to-Risk Context: What the Trials Showed on the Benefit Side

Understanding the side effect burden requires knowing what benefit patients received. Across the three key trials, flibanserin increased satisfying sexual events (SSEs) by approximately 0.5 events per month above placebo. The FDA's advisory committee found this effect modest but clinically meaningful to some patients. A 2016 JAMA Internal Medicine commentary examined the benefit-risk calculation for flibanserin.

A 2015 Cochrane-style systematic review published in JAMA Internal Medicine (Jaspers et al., N=5,914 across eight trials) reported: "Flibanserin was associated with an increase of 0.5 satisfying sexual events per month and improvements in distress, but also with an increase in dizziness, somnolence, and nausea." Read the full Jaspers meta-analysis here.

The HealthRX clinical team uses the following decision framework when reviewing flibanserin candidates: patients should be excluded from prescribing consideration if they consume more than seven alcoholic drinks per week, take any moderate or strong CYP3A4 inhibitor without a feasible washout, have a baseline systolic blood pressure below 100 mmHg, or report prior syncopal episodes. This four-point exclusion screen is applied before any REMS certification step.

Managing and Monitoring Adverse Events in Clinical Practice

Titration and Timing Strategies

No dose titration option exists for flibanserin, the approved dose is 100 mg once daily at bedtime, period. There is no 50 mg starting dose in the label. The bedtime instruction exists to reduce the clinical impact of peak-concentration sedation, not to eliminate it. Patients should be warned that dizziness on standing in the first few hours after waking is possible, particularly in the first two to four weeks of use. The prescribing information provides specific administration guidance.

When to Discontinue

The FDA label recommends stopping flibanserin if no improvement in HSDD symptoms is evident after eight weeks of nightly use. Given that approximately 13% of trial participants discontinued due to adverse events, clinicians should schedule a check-in call or message at two to four weeks to assess tolerability before the eight-week efficacy assessment. The North American Menopause Society published a 2022 position statement on HSDD management that addresses flibanserin follow-up intervals.

Patient Counseling Points Supported by Trial Data

Three counseling points are directly anchored in trial-level data. First, dizziness is the single most common adverse event (11.4%) and usually peaks in the first two to four weeks. Second, no alcohol within two hours of taking the pill and not taking the pill within two hours of drinking, this instruction comes from the alcohol interaction study, not from general caution. Third, grapefruit juice should be avoided because grapefruit is a moderate CYP3A4 inhibitor, and even moderate inhibition raises flibanserin AUC meaningfully based on the fluconazole PK study. These counseling points align with FDA-approved labeling.

Rare and Serious Adverse Events: Full Inventory

The FDA label lists the following as rare but serious: syncope (0.4% in trials), severe hypotension, and appendicitis (reported at numerically similar rates in both arms, not considered drug-related). Hypersensitivity reactions including urticaria and angioedema have appeared in post-market FAERS reports at a frequency classified as "rare" (fewer than 1 in 1,000 patients). Post-market safety updates appear on the FDA drug information page for Addyi.

Suicidal ideation was flagged during the FDA review as a theoretical concern given flibanserin's serotonergic mechanism, but the phase III database did not show a statistically significant difference in depression or suicidal ideation between arms. Nonetheless, prescribers managing patients with active depression should note that the interaction between flibanserin and SSRIs has not been formally studied in a randomized design, and SSRIs are listed as moderate CYP3A4 inhibitors in some drug interaction databases. The FDA clinical review addresses psychiatric adverse events in Section 8.